Business Context and Reporting Period
This Form 8-K Current Report was filed by Syndax Pharmaceuticals, Inc. on January 4, 2017. The report discloses corporate governance changes effective immediately on the filing date.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on director compensation and equity awards.
- Annual Cash Compensation: $35,000 for Board service, paid in quarterly installments.
- Initial Equity Grant: One-time option to purchase 20,000 shares of common stock.
- Vesting Schedule: 1/36 of shares vest monthly over a three-year period.
- Expense Reimbursement: Travel expenses incurred for Board meetings will be reimbursed.
Material Changes
The Board of Directors increased its size to ten members and elected Pierre Legault as a new Class I director. No related person transactions or special arrangements were disclosed regarding his selection.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The only risk-related disclosure notes that the equity award is subject to Mr. Legault's continued service on the Board. Mr. Legault entered into the Company's standard Indemnification Agreement.
Investor Verification Checklist
- Verify the total number of outstanding shares to assess the dilution impact of the 20,000-share option grant.
- Confirm the current Board composition and the term expiration date for the new Class I director.
- Review the Company's Non-Employee Director Compensation Policy for details on future annual option awards.
- Check for any subsequent filings regarding the vesting status or exercise of the granted options.